Jaguar Gene Therapy

Jaguar Gene Therapy is accelerating breakthrough gene therapies for patients with severe genetic disorders. Led by the former AveXis leadership team and backed by healthcare investment firm Deerfield Management, Jaguar Gene Therapy streamlines R&D, manufacturing, and clinical operations to expedite the development and potential approval of therapies for serious genetic diseases. The company’s current pipeline leverages the proven, well-characterized AAV9 vector, targeting diseases with significant unmet needs, including galactosemia, genetic causes of autism spectrum disorder, type 1 diabetes, and Bardet-Biedl syndrome.